Angiotensin II-induced TLR4 mediated abdominal aortic aneurysm in apolipoprotein E knockout mice is dependent on STAT3

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1016/j.yjmcc.2015.08.014</td>
</tr>
<tr>
<td>Accessed</td>
<td>June 28, 2018 3:23:44 PM EDT</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:23032813">http://nrs.harvard.edu/urn-3:HUL.InstRepos:23032813</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP</a></td>
</tr>
</tbody>
</table>

(Article begins on next page)
Angiotensin II-induced TLR4 mediated abdominal aortic aneurysm in Apolipoprotein E knockout mice is dependent on STAT3

Zhexue Qin¹,², Jessamyn Bagley¹, Galina Sukhova³, Wendy E. Baur¹, Ho-Jin Park¹, Debbie Beasley¹, Peter Libby³, Yali Zhang¹,⁵, and Jonas B. Galper¹,⁴,⁵

¹Molecular Cardiology Research Institute, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, 02111

²Dr. Qin’s current address: Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China

³Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 02113

⁴Cardiovascular Center, Division of Cardiology, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston MA 02111

⁵Corresponding authors: Yali Zhang, Molecular Cardiology Research Institute, Tufts Medical Center, 750 Washington St. Boston MA, USA Tel. 617-636-9003; E-mail yzhang2@tuftsmedicalcenter.org; Jonas B. Galper, 750 Washington St. Boston MA, Tel. 617-636-9004, E-mail jgalper@tuftsmedicalcenter.org
Abstract

Abdominal Aortic Aneurysm (AAA) is a major cause of mortality and morbidity in men over 65 years of age. Male apolipoprotein E knockout (ApoE−/−) mice infused with angiotensin II (AngII) develop AAA. Although AngII stimulates both JAK/STAT and Toll-like receptor 4 (TLR4) signaling pathways, their involvement in AngII-mediated AAA formation is unclear. Here we used the small molecule STAT3 inhibitor, S3I-201, the TLR4 inhibitor Eritoran and ApoE−/−TLR4−/− mice to evaluate the interaction between STAT3 and TLR4 signaling in AngII-induced AAA formation. ApoE−/− mice infused for 28 days with AngII developed AAAs and increased STAT3 activation and TLR4 expression. Moreover, AngII increased macrophage infiltration and the ratio of M1 (pro-inflammatory)/M2 (healing) macrophages in aneurysmal tissue as early as 7-10 days after AngII infusion. STAT3 inhibition with S3I-201 decreased the incidence and severity of AngII-induced AAA formation and decreased MMP activity and the ratio of M1/M2 macrophages. Furthermore, AngII-mediated AAA formation, MMP secretion, STAT3 phosphorylation and the ratio of M1/M2 macrophages were markedly decreased in ApoE−/−TLR4−/− mice, and in Eritoran-treated ApoE−/− mice. TLR4 and pSTAT3 levels were also increased in human aneurysmal tissue. These data support a role of pSTAT3 in TLR4 dependent AAA formation and possible therapeutic roles for TLR4 and/or STAT3 inhibition in AAA.

Key words: abdominal aortic aneurysm, toll-like receptor 4, STAT3, angiotensin II
1. Introduction

Abdominal aortic aneurysm (AAA) affects about 8% of men over the age of 65 years in the US, with an annual mortality of more than 15,000.[1-3] Currently, surgical open repair and endovascular repair with stenting remain the only treatment for AAA. Although several molecular mechanisms have been implicated in the pathogenesis of AAA,[4] pathways susceptible to medical therapy that may limit or inhibit aneurysm progression have not been validated.

The development of AAAs in response to Angiotensin II (AngII) in ApoE−/− mice is a widely accepted animal model for AAA formation. In this model the early events in aneurysm formation involve accumulation of inflammatory cells in the adventitia either via recruitment of circulating monocytes or the proliferation of resident macrophages.[5-7] Macrophages exist in several subsets with distinct functions. M1 macrophages mediate pro-inflammatory responses while M2 macrophages exert anti-inflammatory effects and regulate wound healing.[8] M1 macrophages release and activate matrix metalloproteinases (MMPs) which can degrade extracellular matrix and elastic laminae and thus promote dilatation of the lumen and thrombus formation.[5] The combination of the inflammatory response, degradation of extracellular matrix constituents including elastin, and resulting alterations of blood flow and the development ischemia due to thrombus formation result in cellular loss and can promote rupture of the aortic wall.

The Toll-like receptor (TLR) family of molecular pattern recognition receptors serves as cellular sensors for both pathogen-derived and endogenous danger-associated molecular patterns. TLR activation results in rapid recruitment of inflammatory cells and the local production of pro-inflammatory mediators. TLR4 promotes atherosclerosis in mouse models[9, 10] and has recently been implicated in AAA formation.[11]

The Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway transduces a multitude of signals involved in development, homeostasis and inflammation.[12] Ligand binding to receptors activates JAK and STAT proteins which are phosphorylated and form homo or heterodimers which then translocate into the nucleus where they regulate gene expression.[12] In mammals, the JAK/STAT pathway transduces signals for a wide array of cytokines and growth factors including AngII, TNF-α, IL-1β, IL-6 and IFN-γ all of which have been implicated in AAA formation.[13-15] Stimulation of IL-6 and IL-1 production by bacterial lipopolysaccharide (LPS), a TLR4 agonist, in a macrophage cell line is decreased after treatment with either a STAT3 inhibitor or after silencing with a STAT3 siRNA consistent with a role for STAT3 in TLR4 signaling.[16] The role of the JAK/STAT pathway in TLR4 signaling and AngII-mediated AAA formation is, however, unclear. Here we demonstrate that AngII-mediated AAA formation potentiates expression of TLR4 and increases the ratio of M1/M2 macrophages in the abdominal aorta via a STAT3 dependent pathway. Pharmacological inhibition of TLR4 or STAT3 markedly attenuates the incidence and severity of AAAs in AngII-treated ApoE−/− mice suggesting a role of STAT3 dependent TLR4 signaling in the pathogenesis of AAA formation.

2. Methods

An expanded Methods section can be found in the supplemental materials.

2.1 Mice
Male ApoE−/− mice on a C57BL/6J background were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred in a pathogen-free environment. ApoE−/− and TLR4−/− mice were crossbred to obtain ApoE−/−TLR4−/− double knockout mice.[9] Four month-old male mice were used for all experiments. All mice were maintained on a normal mouse chow diet. Animal care and the experimental procedures were carried out in accordance with National Institute of Health guidelines and approved by the Tufts Institutional Animal Care and Use Committee.

2.2 Drug treatment

Alzet osmotic minipumps (Model 2004, Durect, CA, USA) were implanted into ApoE−/− or ApoE−/−TLR4−/− mice to deliver 750 ng/kg/min of AngII (Phoenix Pharmaceuticals, Inc.) subcutaneously for 28 days.[5, 17] Placebo, STAT3 inhibitor S3I-201 (5 mg/kg, i.p., every other day, Selleckchem) or TLR4 antagonist Eritoran (0.3 mg/kg, i.v., every other day, Eisai Inc.) were given for 28 days. S3I-201 inhibits STAT3 phosphorylation with an IC_{50}= 86 µM. The dose of S3I-201 was based on the dose of the drug that inhibited STAT3 dependent growth of breast tumor cells in mice treated every other day for 15 days.[18] The dose of Eritoran was based on the daily i.v. bolus required to maintain blood levels at 50-100 ng/mL over 2 days and to inhibit the increase in TNFα levels in mice treated with LPS.[19]

2.3 Determination of blood pressure and lipids

Systolic blood pressures and lipids were measured as described.[17]

2.4 Classification of aneurysms and measurement of aortic diameter

The aorta was exposed under a dissecting microscope, and the peri-adventitial tissue was removed. Aneurysm severity was rated from Type I to IV according to the method of Daugherty et al.[20]: Type I, dilated lumen without thrombus; Type II, remodeled aneurysmal tissue with little thrombus; Type III, a pronounced bulbous form of Type II with thrombus; Type IV, multiple, often overlapping aneurysms containing thrombus. The outer diameter of the suprarenal aorta was measured with a caliper.

2.5 Tissue harvesting

After the aorta was exposed, the aneurysmal segment of the aorta was harvested, snap frozen in liquid nitrogen, and then stored at -80°C pending further processing for western blot and quantitative RT-PCR (qPCR) analysis. Human aneurysmal specimens were routinely discarded tissues obtained from patients at the time of AAA repair or from normal donors. All specimens were obtained by protocols approved by the Human Investigation Review Committee at Brigham and Women’s Hospital.[21]

2.6 Western Blotting

Tissue was taken for analysis from the suprarenal aorta and included the aneurysm if present. Protein lysates were obtained from the corresponding regions of aneurysmal tissue. Western blot analysis was performed as previously described.[17] The Tyr705 specific pSTAT3 and total STAT3 antibodies were obtained from Cell Signaling Technology; the TLR4 and GAPDH antibodies were obtained from Santa Cruz
Bionotechnology. The protein bands were visualized using chemiluminescent substrates (Pierce).

2.7 Histology
Perfusion-fixed aortas were embedded in paraffin, cut in cross-section (5~10 μm) and stained with hematoxylin and eosin (H&E) and Verhoeff-van Gieson (VVG) for elastin.

2.8 Gelatin Zymography
MMP-2 and MMP-9 activities in homogenates of aortic tissue or conditioned media from cell cultures were determined by zymography as previously described.[22]

2.9 Scoring of elastin breaks and aortic wall thickness
Elastin integrity was graded after VVG staining as described previously. [23] Wall thickness was measured on cross sections from aorta through all three layers of the aortic wall: intima, media, and adventitia.[24]

2.10 Isolation of RNA and quantitative RT-PCR
RNA was isolated using an RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. One microgram of RNA sample was then used for reverse transcription and synthesis of cDNA using the Superscript III First-Strand system (Invitrogen). Quantitative real-time PCR was performed on a Mastercycler ep realplex ² (Eppendorf) using SYBR Green PCR Master Mix (Qiagen). GAPDH expression was used as internal reference in all PCR experiments. RT-PCR primers (Supplemental Table III) for specific target genes were designed based on their reported sequences and synthesized by the Tufts University Core Facility.

2.11 Mouse bone marrow derived macrophages (BMDMs)
BMDMs were used as an in vitro model for studies of the mechanism of macrophage regulation in response to AngII. BMDMs were obtained by flushing the femurs from either ApoE⁻/⁻ or ApoE⁻/⁻TLR4⁻/⁻ mice. Cells were cultured as previously described,[25] and BMDMs were treated with AngII (0.25-2 μM) or LPS (10 ng/mL, List Biological Laboratories Inc., CA) for 16 hours. The medium was collected for MMP assay, and cell lysates for western blot analysis.

2.12 Mouse vascular smooth muscle cells (VSMCs)
Aortic VSMCs from each of five ApoE⁻/⁻ or ApoE⁻/⁻TLR4⁻/⁻ mice were obtained by the explant method as described previously.[26] Cultured cells were identified as VSMCs by immunostaining for smooth muscle-specific α-actin according to the manufacturer’s instructions (Sigma Chemical Co.).

2.13 Flow cytometry analysis
Aortas were harvested as described and digested following the method of Galkina et al.[27] Detailed information can be found in the supplemental materials. Cells were filtered, and cell surface staining was performed as previously described[28] using anti-
CD11b (M1/70, BD Pharmingen), anti-CD11c (HL3, BD Pharmingen), anti-CD206 (C068C2 Biolegend), anti-MHC class II (MS114.15.2, eBioscience), anti-F4/80 (BM8 eBioscience), anti-CD90 (30H12, eBioscience), anti-DX5 (BD Pharmingen), anti-NK1.1 (BD Pharmingen), anti-B220 (RA3-6B2, BD Pharmingen) and anti-Ly6G (1A8, Biolegend). Cellular fluorescence was analyzed using a FacsCanto II cytometer (BD Biosciences, San Jose CA), and data were analyzed using FlowJo software (Tree Star, Inc. Ashland OR).

2.14 Statistical analysis

Data are presented as mean ± SEM. To assess statistical significance, the Kolmogorov-Smirnov test with Lilliefors’ correction was first employed to determine normal distribution. Levene's test was used to test for equality of variances. The student's t-test or Mann-Whitney U test were used for comparison between two groups. Three group comparisons were carried out using one-way ANOVA (LSD Post-hoc test) or the non-parametric Kruskal-Wallis test. To assess statistical significance of aneurysm subtype variables, cross-tabulated contingency tables were constructed and likelihood ratio Chi-square statistics, $LR$ were computed. If $LR$s demonstrated significant differences in the aneurysm severity between treatment groups, then Cramer's $V$ and Goodman and Kruskal Tau tests were performed to assess the strength of the association. $P<0.05$ was considered statistically significant. All analyses were performed with IBM SPSS Statistics 19.0 (IBM Inc., NY).

3. Results

3.1 STAT3 inhibition attenuates the incidence and severity of AngII-induced AAA formation

To test the hypothesis that the JAK/STAT pathway participates in AngII-induced AAA formation in ApoE$^{-/-}$ mice, the level of pSTAT3 in abdominal aortas of AngII and placebo-treated ApoE$^{-/-}$ mice was compared. AngII treatment resulted in a 2.18±0.12 fold increase ($n=4$, $p<0.01$) in the phosphorylation of STAT3 at Tyr705, while total STAT3 (tSTAT3) levels increased by 1.60±0.12 fold ($p<0.05$, Figure 1A and 1B). The increase in total STAT3 in association with increased pSTAT3 is consistent with data demonstrating regulation of STAT3 expression by pSTAT3 dimers.[29] Most importantly, the ratio of pSTAT3/tSTAT3 increased by 1.57±0.06 fold ($n=4$, $p<0.01$). The small molecule STAT3 inhibitor S3I-201 binds with high specificity to the SH2 domain of STAT3, interfering with dimerization and DNA binding.[18] To determine whether the increase in pSTAT3 contributed to the pathogenesis of AngII-induced AAA formation, ApoE$^{-/-}$ mice were treated with either S3I-201 or vehicle. Continuous infusion with S3I-201 significantly reduced the incidence of AAA formation from 84% in the placebo-treated group ($n=19$) to 40% in the S3I-201 treated group ($n=15$, $p<0.05$) (Fig. 1C). Based on the classification system of Daugherty et al.[20] S3I-201 also decreased the severity of the aneurysms (Fig. 1D, supplemental Fig. S1 and supplemental Table I). The distribution of aneurysms was significantly different between the 2 treatment groups as determined by the Likelihood Ratio $\chi^2$ test ($p=0.009$), the Goodman and Kruskal Tau test, and the Cramer's $V$ test, $p<0.05$ for each (Supplemental Table I). Furthermore, the maximal external diameter of the aorta was also significantly decreased from
1.84±0.14mm in placebo-treated mice (n=19) to 1.16±0.07mm in the S3I-201 treated group (n=15, p<0.01) (Fig. 1E). Western blot analysis confirmed that treatment of mice with S3I-201 decreased the ratio of pSTAT3/tSTAT3 in AngII-induced aneurysms from 3.65±0.28 (n=4) to 1.16±0.07 (n=4, p<0.01) fold increase vs. normal aorta (Fig. 1F, G). S3I-201 had no effect on body weight, plasma cholesterol concentration or systolic blood pressure (Supplemental Table II).

3.2 STAT3 inhibition attenuates aortic wall remodeling, elastin degradation and suppresses macrophage infiltration and MMP activity in AngII treated ApoE<sup>−/−</sup> mice.

H&E staining of cross sections taken from the suprarenal region of the aorta demonstrated that AngII treatment resulted in a marked thickening of the abdominal aortic wall. Both the maximal wall thickness and the minimal wall thickness were markedly increased in AngII treated mice, while S3I-201 treatment reduced both maximum and minimum wall thicknesses (Table I, Fig. 2A). Furthermore, treatment with S3I-201 significantly decreased elastin degradation in AAA lesions of AngII-infused ApoE<sup>−/−</sup> mice from grade 1.54 ± 0.09, n=18 to grade 0.99 ± 0.10, (n=16, p<0.01) respectively (Fig. 2A and B), where Elastin integrity of VVG stained sections was graded as: grade 0, no interruption in the medial elastic laminae; grade 1, noticeable interruption in the medial elastic laminae without change of luminal shape; grade 2, prolonged disruption in the elastic laminae with bulbous extension of the aortic lumen.

Table I
Elastin score and wall thickness in ApoE<sup>−/−</sup> mice treated with AngII, S3I-201, and in AngII treated ApoE<sup>−/−</sup>TLR4<sup>−/−</sup> mice

<table>
<thead>
<tr>
<th></th>
<th>ApoE&lt;sup&gt;−/−&lt;/sup&gt;</th>
<th>ApoE&lt;sup&gt;−/−&lt;/sup&gt;TLR4&lt;sup&gt;−/−&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control (n=6)</td>
<td>AngII (n=12)</td>
</tr>
<tr>
<td>Elastin score</td>
<td>N.A</td>
<td>1.540±0.090</td>
</tr>
<tr>
<td>Wall thickness (Maximal, mm)</td>
<td>0.073±0.017</td>
<td>1.315±0.1698**</td>
</tr>
<tr>
<td>Wall thickness (Minimal, mm)</td>
<td>0.004±0.004</td>
<td>0.219±0.078**</td>
</tr>
</tbody>
</table>

All results are expressed as mean±SEM. **P<0.01 compared with control, #P<0.05 and ##P<0.01 compared with AngII group.

In order to determine the role of STAT3 in macrophage infiltration of aneurysmal tissues, CD11b<sup>+</sup>Lin<sup>−</sup>F4/80<sup>+</sup> cells were measured by flow cytometry. As shown in Fig. 2C, AngII infusion promoted macrophage infiltration by 19.75±1.65-fold (n=5, p<0.01 vs. control group), and treatment with S3I-201 decreased macrophage infiltration to 9.59±2.58-fold (n=5, p<0.01 vs. the AngII group). These data are consistent with the well-established role of macrophages in the development of AAAs. Although the source of macrophages in aneurysmal tissue is unclear[2], BMDMs were used as an in vitro model to study the direct effects of AngII on a specific cell type found in the aneurysm. Stimulation with
AngII increased pSTAT3 levels in BMDMs from ApoE−/− mice in a dose-dependent manner with a 1.38±0.05 fold (n=3) increase at 0.25 µM, and a maximal effect of 3.23±0.15 fold (n=3, p<0.05) at 0.5 µM (Supplemental Fig. S2).

MMPs contribute to the initiation and progression of AAA formation,[30] particularly MMP2 and MMP9 which were increased in the abdominal aortas of AngII-treated ApoE−/− mice.[17, 31, 32] To determine whether AngII stimulation of MMP secretion was dependent on pSTAT3, the effect of S3I-201 on MMP2 and MMP9 activity in suprarenal aortas of AngII-treated ApoE−/− mice was measured. S3I-201 treatment significantly down-regulated MMP9 activity (9.50±0.65 vs. 1.73±0.31 fold in AngII and AngII+S3I-201 treated mice, respectively), and MMP2 activity (5.10±0.28 vs. 1.73±0.14 fold, n=4, p<0.01) (Fig. 2D and E).

Vascular smooth muscle cells are a major component of the aortic wall and have been implicated in synthesis of extracellular matrix, protease activity and recruitment of inflammatory cells.[33] To further establish the role of STAT3 in AAA formation, we used VSMCs as a second in vitro model to study the role of pSTAT3 in the pathogenesis of AAAs. VSMCs were starved in DMEM for 8 hours followed by treatment with 0.5µM AngII for 16 hours. S3I-201 (100 µM) or vehicle was added 1 hour prior to AngII. Cells were harvested for western blot analysis and medium for zymographic analysis. pSTAT3 levels increased 1.89±0.08 fold, while MMP2 levels increased 1.69±0.12 fold (n=4, P<0.05), while treatment with S3I-201 completely reversed this effect (Supplementary Fig. S3).

3.3 The ratio of M1/M2 macrophages is increased in AngII-induced AAA formation and STAT3 inhibition markedly reverses M1 polarization

At least 2 subsets of macrophages have been described based on functional phenotype. Pro-inflammatory M1 macrophages are characterized by the cell surface marker CD11c, high surface expression of MHC class II and the intracellular marker iNOS. “Healing” M2 macrophages are characterized by the cell surface marker CD206 and intracellular marker Ym-1. Flow cytometry analysis based on the cell surface markers was used to determine the M1 and M2 subtypes (Supplemental Fig. S4). Since no combination of cell surface markers is able to unequivocally identify M1/M2 macrophages, qPCR analysis for expression of iNOS and Ym-1 was further used to validate flow cytometry data.

In order to determine whether macrophage infiltration and macrophage phenotype play a role in the early events of AAA formation, the suprarenal aortas from ApoE−/− mice 7-10 days after AngII treatment were used for flow cytometry. At this time point only 2 out of 16 mice (13%) developed AAAs. Flow cytometric analysis of the suprarenal aortas from 6 of these mice with no visible evidence of AAAs demonstrated a 2.91±0.45 fold increase (n=6, p<0.01) in total macrophages compared to control as determined by CD11b+Lin−F4/80+ cells (Fig. 3A). Importantly, the ratio of M1/M2 was significantly increased by 3.07±0.82 fold (n=6, p<0.05, Fig. 3A). These data supported the conclusion that macrophage accumulation and an increase in the ratio of M1/M2 phenotype are early pro-inflammatory events in AAA formation. Furthermore, after 28 days of AngII treatment, total macrophages increased 19.75±1.65 fold compared to control (Fig. 2C), while the ratio of M1/M2 macrophages increased 5.87±0.73 fold (n=4, p<0.01, Fig. 3B and C). Importantly, S3I-201 treatment not only markedly decreased
total macrophage infiltration (Fig. 2C) but also significantly decreased the ratio of M1/M2 macrophages to 2.93±0.34 fold (n=5, p<0.01) above control (Fig. 3B and C). These findings were further supported by qPCR analysis of mRNA levels of iNOS, an M1 marker and Ym-1, an M2 marker. AngII infusion increased iNOS mRNA expression in aneurysmal tissue 66.87±5.80 fold (n=4, p<0.01) above the control, while treatment with S3I-201 decreased iNOS mRNA level to 12.76±3.58 fold above control (n=4, p<0.01). Conversely, AngII infusion decreased Ym-1 mRNA to 0.44±0.11 fold (n=4, p<0.01), while S3I-201 treatment increased Ym-1 to 1.24±0.32 fold (n=4, p<0.01). Additionally, the ratio of iNOS/Ym-1 increased 145.44±22.42 fold (n=4, p<0.01) in response to AngII, but increased to only 9.65±3.51 (n=4, p<0.01) in response to AngII plus S3I-201 treatment (Fig. 3D). These data supported the conclusion that the AngII mediated increase in pro-inflammatory macrophages in the suprarenal aortas of ApoE⁻/⁻ mice was dependent at least in part on pSTAT3.

3.4 AngII up-regulates the expression of TLR4
Recent evidence supports a role of TLR4 signaling in the pathogenesis of AngII-induced aortic aneurysms in LDLR⁻/⁻ mice. To further investigate the role of TLR4 in AngII-induced AAA formation, we determined whether TLR4 expression was increased in aneurysms in these mice. TLR4 mRNA level determined by qPCR were 4.76±0.72 fold higher (n=5, p<0.01) in the suprarenal aorta of AngII treated mice compared with control (Fig. 4A). Furthermore, western blot analysis demonstrated that TLR4 protein level was also increased 1.78±0.15 fold (n=4, p<0.05) in AngII-treated mice compared to control (Fig. 4B and C). To validate this effect of AngII on macrophages in vitro, we determined the effect of AngII on TLR4 levels in BMDMs. Data outlined in Supplemental Fig. S5 demonstrate that AngII increased TLR4 protein expression in BMDMs from ApoE⁻/⁻ mice in a dose-dependent manner.

3.5 TLR4 deficiency attenuates AngII-induced pSTAT3
AngII mediated AAA formation had been shown to be dependent on TLR4[11]. Here we determined whether AngII mediated activation of STAT3 was also dependent on TLR4. We determined the effect of AngII treatment on AAA formation in an ApoE⁻/⁻/TLR4⁻/⁻ mouse. The incidence and severity of AAA formation were both significantly reduced in ApoE⁻/⁻/TLR4⁻/⁻ mice compared to the ApoE⁻/⁻ controls (Fig. 4D and E). AAA incidence decreased from 80% in ApoE⁻/⁻ mice (n=20) to 39% in ApoE⁻/⁻/TLR4⁻/⁻ mice (n=18, p<0.05). AAA severity also decreased in AngII treated ApoE⁻/⁻/TLR4⁻/⁻ mice compared with ApoE⁻/⁻ mice: 65% of ApoE⁻/⁻ mice treated with AngII developed either type III or type IV aneurysms compared with 17% of ApoE⁻/⁻/TLR4⁻/⁻ mice (Fig. 4E, Supplemental Table I). The distribution of aneurysms was significantly different between the 2 treatment groups as determined by the Likelihood Ratio test (p=0.002), the Goodman and Kruskal Tau test, and the Cramer's V test, p<0.007 for each (Supplemental Table I). In addition, the maximal aortic diameter decreased from 1.89±0.18mm (n=20) in ApoE⁻/⁻ mice to 1.26±0.20mm (n=18, p<0.05) in ApoE⁻/⁻/TLR4⁻/⁻ mice (Fig. 4F). Furthermore, the elastin score decreased significantly in the suprarenal aorta of the AngII treated ApoE⁻/⁻/TLR4⁻/⁻ mouse compared to the AngII treated ApoE⁻/⁻ mice (Table I, Supplemental Fig. S6). Similarly, both maximal and minimal aortic wall thickness were significantly decreased in the ApoE⁻/⁻/TLR4⁻/⁻ mice compared with the
ApoE−/− (Table I, Supplemental Fig. S6) consistent with a marked decrease in aneurysm severity. Additionally, TLR4 deficiency resulted in a significant down-regulation of AngII stimulated MMP9 and MMP2 activity (Fig. 5A, B). Systolic blood pressure, serum cholesterol level and body weight did not differ significantly between ApoE−/− and ApoE−/−TLR4−/− mice (Supplemental Table II).

Finally to determine whether the increase in pSTAT3 found in AngII-induced aneurysms is dependent on TLR4 signaling, we compared levels of STAT3 phosphorylation in homogenates of the suprarenal aortas from AngII-treated ApoE−/− and ApoE−/−TLR4−/− mice. Knockout of TLR4 resulted in a decrease in AngII-mediated pSTAT3 from 2.64±0.15 fold above control to 1.56±0.30 fold (n=4, p<0.01, Fig. 5C and D) consistent with a role of TLR4 in pSTAT3-mediated AAA formation. The link between TLR4 and AngII-induced pSTAT3 is further supported by the finding that treatment of BMDMs from ApoE−/− mice with either AngII or LPS increased pSTAT3 levels, by 6.41±2.48 fold (n=3, p<0.05) and 12.17±1.99 fold (n=3, p<0.05) respectively. Neither AngII nor LPS had an effect on pSTAT3 in BMDMs from ApoE−/−TLR4−/− (Fig. 5E and F).

The role of TLR4 in AAA formation is further supported by the finding that AngII mediated STAT3 activation and MMP2 secretion in VSMCs cultured from ApoE−/− mice, was abolished by TLR4 deficiency (Fig. S7).

3.6 TLR4 deficiency attenuates the AngII-induced increase in M1/M2 ratio

To determine whether the AngII-induced increase in M1 macrophages and M1/M2 ratio were dependent on TLR4 signaling, the effect of AngII on macrophage phenotypes in the suprarenal aortas of ApoE−/−TLR4−/− mice was determined by qPCR analysis. TLR4 deficiency in AngII treated mice decreased iNOS expression from 47.20±21.21 fold above control (n=4, p<0.01) in ApoE−/− mice to 5.76±0.53 fold (n=4, p<0.01) above control in ApoE−/−TLR4−/− mice consistent with a marked decrease in M1 phenotype in the TLR4−/− mouse. Conversely, compared to control, TLR4 deficiency in AngII treated mice increased Ym-1 expression from 0.75±0.19 fold (n=4, p<0.05) in ApoE−/− mice to 2.85±0.66 fold (n=4, p<0.01) in ApoE−/−TLR4−/− mice consistent with an increase in the M2 phenotype. Additionally the ratio of iNOS/Ym-1 in AngII-treated mice decreased from 85.27±50.48 fold (n=4, p<0.05) above control in ApoE−/− mice to 2.12±0.59 (n=4, p<0.05, Fig. 5E) in ApoE−/−TLR4−/− mice.

3.7 Eritoran, a small molecule TLR4 Inhibitor, attenuates AngII-induced AAA formation, STAT3 stimulation, MMP activity and M1/M2 ratio

Given data supporting a role of TLR4 in AngII-induced AAA formation,[11] we determined whether TLR4 inhibitors might have therapeutic potential in the treatment of AAAs. A number of small molecule TLR4 inhibitors have been developed for the treatment of sepsis, including Eritoran (Eisai, Inc.).[34] To determine the effect of pharmacologic inhibition of TLR4 on aneurysm formation, ApoE−/− mice receiving continuous AngII infusion were treated with either placebo or Eritoran (300 µg/kg, i.v.) every other day. Eritoran treatment decreased the incidence of AAA formation from 80% to 44% (n=10 and 9 respectively, Fig. 6A). AAA severity also decreased in Eritoran treated mice compared with placebo treated: 60% of placebo-treated mice developed either type III or type IV aneurysms compared with 33% of mice that developed type III aneurysms while no type IV aneurysms were found in Eritoran-treated mice. Eritoran
treatment also significantly reduced maximal aortic diameter from 1.91±0.18 mm (n=10) to 1.35±0.19 mm (n=9, p<0.05) (Fig. 6B). Eritoran had no effect on body weight, plasma cholesterol and systolic blood pressure (Supplemental Table II).

Additionally, Eritoran treatment significantly down-regulated AngII-stimulated MMP9 activity from 16.39±1.64 to 1.62±0.30 fold and MMP2 activity from 7.80±0.43 to 2.19±0.76 fold respectively above those in control mice (n=4, p<0.01, Fig. 6C and D). Furthermore, Eritoran significantly attenuated AngII-stimulated pSTAT3 levels from 3.08±0.56 fold to 1.76±0.36 fold compared with control (n=4, p<0.05) (Fig. 6E and F) and inhibited the AngII-mediated increase in M1/M2 ratio. The mRNA level of iNOS significantly decreased from 39.65±8.10 to 8.49±0.54 fold (n=4, p<0.01), while the mRNA level of Ym-1 increased from 0.48±0.12 to 1.23±0.34 fold (n=4, p<0.05) in Eritoran treated mice. Finally, the ratio of iNOS/Ym-1 decreased from 105.21±40.94 to 7.20±1.45 fold (n=4, p<0.01) by Eritoran (Fig. 6G).

3.8 Increased TLR4 expression and STAT3 activation in human AAAs

In order to test the potential clinical relevance of our findings, the levels of TLR4 and pSTAT3 in human AAA tissue were measured. Aortic aneurysmal tissue taken from AAA patients at the time of open surgical repair demonstrated significantly higher levels of TLR4, pSTAT3 and tSTAT3 1.99±0.25, 2.04±0.08 and 1.22±0.02 fold respectively, compared to aortic tissue from normal donors without AAA (n=4, p<0.05, Fig. 7A and B).

4. Discussion

These data support the conclusion that the incidence and severity of AngII-induced AAA formation in ApoE−/− mice depends at least in part on the AngII-mediated activation of STAT3. Furthermore, the finding that both AngII-mediated AAA formation and STAT3 phosphorylation are markedly attenuated in ApoE−/TLR4−/ mice and in ApoE−/ mice treated with the TLR4 inhibitor Eritoran strongly supports the conclusion that AngII stimulates STAT3, by mechanisms that involve TLR4 signaling (Fig. 7C). The finding that AngII markedly increased macrophage infiltration in the suprarenal aorta with a predominant increase in the ratio of pro-inflammatory M1 macrophages to anti-inflammatory/healing M2 macrophages at an early time point (7-10 days after AngII infusion) when there is little anatomical evidence of AAA formation, is consistent with the conclusion that macrophage infiltration is an early event in AAA formation, and that M1 macrophages may play an early role in the pathogenesis of AAAs in this model. After 28 days of AngII infusion, at a time when 84% of animals develop AAA, we observe a further increase in both the extent of macrophage infiltration and an increase in the ratio of M1/M2 macrophages. Importantly the increase in the M1/M2 ratio at day 28 was reversed by inhibition of either STAT3 or TLR4 signaling. The observed increase in M1/M2 macrophages may be due to proliferation of resident macrophages or macrophage differentiation of circulating monocytes after infiltration of the aortic wall. Furthermore, recent data suggest that everolimus, an mTOR inhibitor, attenuated M1 polarization in ApoE−/− BMDMs in vitro and AAA formation in vivo.[35] The choice of BMDM as an in vitro model for changes observed in the intact suprarenal aorta is complicated by a recent bone marrow transplant study in which donor marrow from cholesterol fed LDLR−/−TLR4−/ mice had no effect on the increase in aortic diameter in cholesterol fed LDLR−/− recipient mice treated with high doses of AngII.[11] However,
given that increased levels of macrophages is well established in the pathogenesis of AAA, whether these cells migrated from the spleen, the bone marrow or represent proliferation of resident macrophages, does not preclude the use of BMDM as an in vitro model for studies of the mechanism of macrophages regulation in response to AngII. Using BMDM, we determined that the levels of pSTAT3 and TLR4 were dose dependently increased in response to AngII. Given the preponderance of VSMCs in the wall of the aorta and data supporting a role of VSMCs in AAA formation[33], we used VSMCs as second in vitro model. Data demonstrated that increased pSTAT3 and MMP secretion in VSMCs in response to AngII which was dependent on TLR4 signaling further supporting the validity of the conclusions derived from homogenates of the suprarenal aortas.

The role of TLR4 in the pathogenesis of AAAs is supported by recent data demonstrating a decreased incidence of AAA formation in cholesterol fed LDLR−/− TLR4−/− mice treated with AngII.[11] Here we demonstrate that the incidence and severity of AAA formation were markedly decreased in AngII-treated ApoE−/− that were TLR4-deficient, or were treated with a small molecule TLR4 inhibitor. Furthermore the finding that stimulation of STAT3 phosphorylation in response to both AngII and LPS was markedly attenuated in BMDM from ApoE−/−TLR4−/− mice further support the role of TLR4 in STAT3 mediated AAA formation. The finding that TLR4 expression is increased in the suprarenal aorta of AngII treated ApoE−/− mice and that AngII dose dependently increased TLR4 expression in BMDM from ApoE−/− mice is consistent with a potentiation of TLR4 signaling in response to AngII. Recently, Greenhill et al. demonstrated that mice with hyper-expression of the IL6 cytokine receptor subunit gp130 are hyper-responsive to the TLR4 ligand LPS.[36] This effect was significantly attenuated in STAT3−/− gp130 overexpressing mice indicating a role of STAT3 in TLR4 signaling. However, in another study, STAT3 knockdown potentiated TLR4 dependent ischemia/reperfusion injury in mouse liver.[37] These data suggest pleiotropic effects of STAT3 potentiating or attenuating TLR4 signaling in different disease models. Importantly, treatment of ApoE−/− mice with Eritoran not only significantly decreased the incidence and severity of AAAs, but also interfered with AngII-mediated secretion of MMPs and the accumulation of M1 macrophages in the suprarenal aortas of ApoE−/− mice consistent with a potential therapeutic role for TLR4 inhibitors in the treatment of AAAs.

Although the role of the JAK/STAT pathway in AngII signaling is supported by studies which demonstrate the binding of JAK2 to angiotensin receptor 1 and the activation of STAT1 and STAT2 in vascular smooth muscle cells[13] and the activation of STAT3 in rat cardiomyocytes,[38] its role in the pathogenesis of AAAs is unclear. Our data demonstrate a role for AngII in the activation of STAT3 in the pathogenesis of AAAs. Specifically, S3I-201, a small molecule inhibitor with a high degree of specificity for STAT3, which interferes with dimerization of STAT3,[18] markedly decreased both the incidence and severity of AAAs, MMP secretion, macrophage infiltration and M1/M2 ratio in an AngII-induced ApoE−/− mouse model. Recent data demonstrating the association of a variant of the IL-6 receptor with decreased incidence of AAAs and decreased expression of STAT3,[39] further suggested a role of STAT3 in AAA formation. Furthermore, in a recent study aged C57BL/6 mice treated with very high doses of AngII (2500 ng/kg) developed aortic dilatation that was attenuated by a STAT3
inhibitor peptide.[40] Consistent with these findings, our data demonstrated a marked elevation of pSTAT3 and total STAT3, as well as TLR4 in tissue samples obtained from patients during AAA repair compared with levels in non-aneurysmal aortic tissue from organ donors. These data are consistent with the findings of a recent study demonstrating increased pSTAT3 in patients with AAAs.[41] Interestingly, in a different model of AngII mediated AAA formation in which C57BL/6 wild-type mice were treated with neutralization antibody to TGFβ, selective deletion of STAT3 in macrophages and neutrophils did not affect aneurysm development.[42] These differences likely reflect differences in the mechanisms of TGFβ effects on AAA formation.

Our study demonstrates roles of both STAT3 and TLR4 signaling in AngII-mediated AAA formation. The role of STAT3 in the pathogenesis of AAAs is further supported by data demonstrating that STAT3 activation is necessary for AngII-stimulated MMP secretion and the increase in total macrophages and the ratio of MI/M2 macrophages in suprarenal aortas of ApoE⁻/⁻ mice. The findings that inhibition of TLR4 signaling by Eritoran and inhibition of STAT3 signaling by S3I-201 significantly decreased the incidence and severity of AAA formation in this mouse model suggest that both TLR4 and STAT3 might serve as therapeutic targets in the treatment of AAAs.

**Supplementary material**

Supplementary material is available online

**Funding**

This study was supported by NIH T32 HL69770 to Dr. Zhang, NIH grants 1R01HL066467 to Dr. Galper, HL47569 and HL113732 to Dr. Beasley and National Natural Science Foundation of China 31301167 to Dr. Qin.

**Acknowledgments**

We thank Eisai Pharmaceuticals for Eritoran

**Disclosures**

None.
References


**Figure Legends**

**Figure 1** The STAT3 inhibitor, S3I-201, decreases the incidence and severity of AAA formation. (A) Effect of AngII on pSTAT3 and tSTAT3 in aneurysmal tissues determined by western blotting. (B) Densitometric analysis of data in A normalized to GAPDH (*p<0.05, **p<0.01 vs. control, n=4 per group). (C) S3I-201 significantly reduced the incidence of AAA formation from 84% (AngII) to 40% (p<0.05, n=19 and 15). (D) S3I-201 significantly reduced the severity of AAA based on the classification of aneurysms. (E) The external diameter of the aorta was also significantly decreased by S3I-201 treatment (##p<0.01 vs. placebo, n=19 and 15). (F & G) S3I-201 decreased AngII-induced pSTAT3/tSTAT3 determined by western blot (**p<0.01 vs. control, ##p<0.01 vs. placebo, n=4).

**Figure 2** S3I-201 attenuates AngII-induced remodeling of the aortic wall, macrophage infiltration and MMP activity in the abdominal aortas. (A) Representative photomicrographs of aortic cross sections. Top, H&E staining, bottom, VVG elastin staining. (B) Area defined by the square in A demonstrating the elastin degradation. (C) S3I-201 significantly decreased the total macrophage (CD11b+Lin F4/80+) infiltration in the abdominal aortas measured by flow cytometry. (D & E) S3I-201 significantly decreased AngII-induced gelatinolytic activities of MMP2 and MMP9 in homogenates of the aortas determined by gelatin zymography (**p<0.01 vs. control, ##p<0.01 vs. placebo, n=4).

**Figure 3** The role of M1/M2 macrophages in AngII-induced AAA formation. (A) Total macrophage and M1/M2 ratio measured by flow cytometry were increased at day 7-10 after AngII treatment (n=6, *p<0.05, **p<0.01 vs. control). (B) The ratio of M1/M2 was further increased by AngII treatment at day 28, while S3I-201 markedly decreased M1/M2 ratio (n=5, **p<0.01 vs. control, ##p<0.01 vs. placebo). (C) Representative plots illustrating identification of M1 macrophage (CD11c+), and M2 macrophage (CD206+) in aortic digests. (D) The effects of AngII and S3I-201 on the expression of iNOS, Ym-1 mRNA and the ratio of iNOS/Ym-1 (n=4, **p<0.01 vs. control, ##p<0.01 vs. placebo).

**Figure 4** Role of TLR4 in AngII-induced AAA formation in ApoE−/− mice. (A) AngII increased the mRNA level of TLR4 in suprarenal aorta determined by qPCR (**p<0.01 vs. control, n=4). (B & C) AngII increased TLR4 protein level determined by western blot analysis (*p<0.05 vs. control, n=4). (D and E) Deficiency of TLR4 significantly reduced the incidence and severity of AAA formation in ApoE−/− mice (p<0.05, n=18 and 20 per group). (F) The maximal aortic diameter was also significantly decreased by TLR4 deficiency (*p<0.05 vs. control, n=18 and 20 per group, respectively).

**Figure 5** TLR4 knockout attenuates AngII-induced pSTAT3 and the ratio of M1/M2. (A & B) TLR4 deficiency decreased AngII-induced pSTAT3 in aortic homogenates (***p<0.001 vs. control, ##p<0.01 vs. ApoE−/−+AngII, n=4). (C & D) TLR4 deficiency attenuated AngII- and LPS- induced activation of pSTAT3 in BMDMs from ApoE−/− mice determined by western blot analysis (**p<0.01 vs. control, n=4). (E) The effect of TLR4
deficiency on iNOS, Ym-1 and the ratio of iNOS/Ym-1 mRNA levels (n=4, *p<0.05 vs. control, **p<0.01 vs. control, ##p<0.01 vs. ApoE⁻/⁻+AngII).

**Figure 6** The TLR4 inhibitor Eritoran decreases the incidence of AngII-induced AAAs, the activation of STAT3 and M1/M2 ratio. (A & B) Eritoran significantly reduced the incidence of AngII-induced AAA formation and the external diameter of the aortas (*p<0.05 vs. placebo, n=9 and 10 per group). (C & D) Eritoran decreased the gelatinolytic activities MMP2 and MMP9 in AngII-treated ApoE⁻/⁻ mice measured by zymography in homogenates of aortas (**p<0.01 vs. control, ##p<0.01 vs. placebo, n=4). (E & F) The activation of STAT3 induced by AngII was significantly decreased by Eritoran, as determined by western blot analysis of homogenates of aortas (*p<0.05 vs. control, #p<0.05 vs. placebo, n=4). (G) The effect of Eritoran on iNOS, Ym-1 and the ratio of iNOS/Ym-1 mRNA levels, as measured by qPCR (n=4, *p<0.05, vs. control, **p<0.01 vs. control, ##p<0.01 vs. placebo).

**Figure 7** Abdominal aortas from patients with AAA demonstrate increased levels of TLR4, pSTAT3 and tSTAT3 compared to normal donor aortas. (A & B) Western blot analysis of TLR4, pSTAT3, tSTAT3 in tissue homogenates of aortic tissue taken at the time of aneurysmal repair and aortas from normal organ donors (*p<0.05 vs. control, n=4). (C) Schematic representation of proposed pathway for the link between STAT3 and TLR4 in AngII-induced of AAA formation.
Figure

A

B

C

D

E

F

G

Fig. 1

AAA Incidence (%)

AAA Incidence (%)

Maximal aortic diameter (mm)

Fold change

pSTAT3/tSTAT3

Control

AngII

Placebo

S3I-201

Control

AngII

Placebo

S3I-201

Control

AngII

Placebo

S3I-201

Control

AngII

Placebo

S3I-201

Control

AngII

Placebo

S3I-201
Fig. 2

A. 

<table>
<thead>
<tr>
<th>Control</th>
<th>Placebo</th>
<th>S3I-201</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;E</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elastin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B. 

![Image of tissue section](image)

200µm

C. 

<table>
<thead>
<tr>
<th>CD11b^+Lin-F4/80^-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
</tr>
<tr>
<td>AngII + Placebo</td>
</tr>
<tr>
<td>AngII + S3I-201</td>
</tr>
</tbody>
</table>

Fold change

D. 

![Image of gel](image)

Pro-MMP9
Act-MMP9
Pro-MMP2
Act-MMP2

E. 

<table>
<thead>
<tr>
<th>Act-MMP2</th>
<th>Act-MMP9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
</tr>
<tr>
<td>AngII + Placebo</td>
<td></td>
</tr>
<tr>
<td>AngII + S3I-201</td>
<td></td>
</tr>
</tbody>
</table>
Fig. 3

A. Fold change of total MΦ and M1/M2 ratio at 7-10 days.

B. Fold change of M1/M2 ratio.

C. Flow cytometry analysis of CD11C and CD206 expression.

D. Fold change of mRNA expression for iNOS, Ym-1, and iNOS/Ym-1.
Fig. 4

**A** TLR4 mRNA

**B** TLR4 protein

**C** TLR4 protein

**D** AAA incidence (%) in ApoE-/- and ApoE-/-TLR4-/- mice

**E** AAA incidence (%) in ApoE-/- and ApoE-/-TLR4-/- mice

**F** Maximal aortic diameter (mm) in ApoE-/- and ApoE-/-TLR4-/- mice
Fig. 5

A. Western blot analysis of pro-MMP9 and act-MMP9 in ApoE-/-, ApoE-/-TLR4-/-, and Vehicle-treated groups.

B. Bar graph showing the fold change of act-MMP2 and act-MMP9 in ApoE-/-, ApoE-/-TLR4-/-, and Vehicle-treated groups.

C. Western blot analysis of pSTAT3, tSTAT3, and GAPDH in ApoE-/- and ApoE-/-TLR4-/- treated with Vehicle or AngII.

D. Bar graph showing the fold change of pSTAT3/tSTAT3 in ApoE-/-, ApoE-/-TLR4-/-, and Vehicle-treated groups.

E. Western blot analysis of pSTAT3, tSTAT3, and GAPDH in ApoE-/- and ApoE-/-TLR4-/- treated with C, AngII, and LPS.

F. Bar graph showing the fold change of pSTAT3/tSTAT3 in ApoE-/-, ApoE-/-TLR4-/-, and Vehicle-treated groups.

G. Bar graphs showing the fold change of iNOS, Ym-1, and iNOS/Ym-1 in ApoE-/- and ApoE-/-TLR4-/- treated with Control, AngII, and LPS.
A

Control AAA

TLR4
pSTAT3
tSTAT3
GAPDH

B

Fold change

0 0.5 1 1.5 2 2.5

TLR4 pSTAT3 tSTAT3

C

AngII TLR4

STAT3

Inflammatory response

MMP2, MMP9

Abdominal Aortic Aneurysm
Supplemental Material

Expanded Methods

2.3 Determination of blood pressure and lipids

Systolic blood pressures were measured in trained, prewarmed conscious mice by using a tail cuff apparatus coupled to a PC-based data acquisition system (Kent Scientific Corporation). To avoid procedure-induced anxiety, mice were initially acclimated to the instrument for 3 consecutive days before the actual measurement. On the fourth day, pressures were measured in both the morning and afternoon. Moreover, the first 5 of 30 blood pressure values at each session were disregarded, and the remaining 25 values were averaged and used for analysis.

Plasma samples were obtained from individual mice at the time of sacrifice for analysis of cholesterol enzymatically (IDEXX Laboratories).

2.8 Gelatin Zymography

MMP-2 and MMP-9 activities in homogenates of aortic tissue or conditioned media from cell cultures were determined by zymography as previously described. Briefly, gelatin zymography was performed under non-reducing conditions on SDS-PAGE gels containing 1 mg/ml porcine gelatin. Gel electrophoresis was performed at 150 V for 1 hour. After electrophoresis, the gel was washed in 2.5% Triton X-100 solution with gentle agitation for 6 hours at room temperature, followed by replacement with developing buffer containing 50 mM Tris-HCl (pH 7.5), 0.2 M NaCl, 5 mM CaCl₂ and 0.2% Brij-35). The gel was agitated at room temperature for 30 min, placed in fresh developing buffer, and incubated at 37 °C overnight. The following morning, gels were stained with 0.5% Coomassie brilliant Blue R-250 in 40% methanol and 10% acetic acid for 2-4 hours and destained in 40% methanol and 10% acetic acid at room temperature. Gelatinolytic bands were quantified by scanning densitometry with NIH ImageJ software.

2.11 Mouse bone marrow derived macrophages (BMDMs)

Macrophages have been found abundant in aneurysmal tissue, though the source of macrophages infiltrating the abdominal aorta in the pathogenesis of AAAs is unclear. BMDMs were used as an in vitro model for studies of the mechanism of macrophage regulation in response to AngII. BMDMs were obtained by flushing the femurs from either ApoE−/− or ApoE−/−TLR4−/− mice. Cells were cultured as previously described in DMEM containing 10% heat inactivated FBS and L929-cell conditioned medium at a final concentration of 30% (v/v) as a source of granulocyte/macrophage colony stimulating factor which drive the bone marrow monocyte/macrophage progenitors to proliferate towards a greater than 95% pure population of macrophages. At Day 7-8, BMDMs were trypsinized, plated in experimental culture dishes and incubated overnight. Next day, cells were starved in DMEM for 8 hours, and then treated with AngII (0.25-2 µM) or LPS (10 ng/mL, List Biological Laboratories Inc., CA) for 16 hours. The medium was collected for MMP assay, and cell lysates for western blot analysis.
2.13 Flow cytometry (FACS) analysis

Aortas were harvested as described and digested following the method of Galkina et al. Briefly, aortas were minced in 2ml digestion buffer (125 U/ml Collagenase type XI, 60 U/ml Hyaluronidase type 1-s, 60 U/ml DNase I, and 450 U/ml Collagenase type I, in PBS) and incubated at 37°C for one hour with shaking. Cells were filtered, and cell surface staining was performed as previously described using anti-CD11b (M1/70, BD Pharmingen), anti-CD11c (HL3, BD Pharmingen), anti-CD206 (C068C2 Biolegend), anti-MHC class II (MS114.15.2, eBioscience), anti-F4/80 (BM8 eBioscience), anti-CD90 (30H12, eBioscience), anti-DX5 (BD Pharmingen), anti-NK1.1 (BD Pharmingen), anti-B220 (RA3-6B2, BD Pharmingen) and anti-Ly6G (1A8, Biolegend). All cytometry was performed on a FacsCanto II cytometer (BD Biosciences, San Jose CA), and data were analyzed using FlowJo software (Tree Star, Inc. Ashland OR).

References

### Supplemental Table I

Crosstabulation Table used for Statistical Analysis of Aneurysm Severity by Treatment

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Aneurysm Type</th>
<th>none</th>
<th>Type I</th>
<th>Type II</th>
<th>Type III</th>
<th>Type IV</th>
<th>total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AngII+Placebo</strong></td>
<td>Count</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>8</td>
<td>5</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>16</td>
<td>0</td>
<td>16</td>
<td>42</td>
<td>26</td>
<td>100</td>
</tr>
<tr>
<td><strong>AngII+S3I-201</strong></td>
<td>Count</td>
<td>9</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>60</td>
<td>7</td>
<td>20</td>
<td>13</td>
<td>0</td>
<td>100</td>
</tr>
</tbody>
</table>

*AngII+Placebo vs. AngII+S3I-201: 13.545 (P=0.009) 0.328 (P=0.029) 0.573 (P=0.025)*

†Likelihood Ratio, ‡Goodman and Kruskal Tau, ††Cramer’s V

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Aneurysm Type</th>
<th>none</th>
<th>Type I</th>
<th>Type II</th>
<th>Type III</th>
<th>Type IV</th>
<th>total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ApoE-/-</strong></td>
<td>Count</td>
<td>4</td>
<td>0</td>
<td>3</td>
<td>9</td>
<td>4</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>20</td>
<td>0</td>
<td>15</td>
<td>45</td>
<td>20</td>
<td>100</td>
</tr>
<tr>
<td><strong>ApoE-/-TLR4-/-</strong></td>
<td>Count</td>
<td>11</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>60</td>
<td>17</td>
<td>6</td>
<td>17</td>
<td>0</td>
<td>100</td>
</tr>
</tbody>
</table>

*ApoE-/- vs. ApoE-/-TLR4-/-: 7.182 (P=0.002) 0.374 (P=0.008) 0.611 (P=0.007)*
## Supplemental Table II

**Systolic blood pressure and total cholesterol in ApoE<sup>−/−</sup> mice treated with Ang II, S3I-201 and Eritoran, and in Ang II treated ApoE<sup>−/−</sup>TLR4<sup>−/−</sup> mice**

<table>
<thead>
<tr>
<th>Genes</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLR4</td>
<td>5'-tggctggtttacatccatcggt-3'</td>
<td>5'-tggcaccattgaagctgaggtcta-3'</td>
</tr>
<tr>
<td>iNOS</td>
<td>5'-gagacgcacaggcaggg-3'</td>
<td>5'-caggcacacgcaatgatgg-3'</td>
</tr>
<tr>
<td>Ym-1</td>
<td>5'-cagaaccgtcagacattcatta-3'</td>
<td>5'-atggtcttccagtaggtaata-3'</td>
</tr>
<tr>
<td>GAPDH</td>
<td>5'-tcaacggcagtcagtcaggg-3'</td>
<td>5'-actccagcatactcagc-3'</td>
</tr>
</tbody>
</table>

SBP was measured using a tail-cuff system. Total cholesterol and body weight were determined at the end of the study. All results are expressed as mean±SEM. *P<0.05 compared with control.
Figure S1 Representative aortas from control, AngII, and AngII+S3I-201 treated ApoE⁻/⁻ mice.
**Supplemental Figure 2**

**Figure S2** AngII stimulates STAT3 phosphorylation in BMDMs from ApoE⁻/⁻ mice in a dose-dependent manner. BMDMs were starved in DMEM for 8 hours followed by treatment with the indicated concentrations of AngII for 16h. **A.** Western blot analysis of pSTAT3 and tSTAT3. **B.** Densitometric analysis of data in A normalized to GAPDH (*P<0.05 vs. control).
**Supplemental Figure 3**

**Figure S3** AngII stimulates STAT3 phosphorylation in VSMCs from ApoE−/− mice. Furthermore, Ang II stimulation of MMP2 secretion in VSMCs is dependent on pSTAT3. (A) pSTAT3 and tSTAT3 determined by western blot analysis of cell homogenates and MMP2 in the growth medium were determined by zymography. B. Densitometric analysis of data in A normalized to GAPDH (*P<0.05, compared to control, #P<0.05, compared to AngII, n=4).
Figure S4 Gating schema for flow cytometric identification of M1/M2 macrophages in aortic digests. Total cells were first gated by forward and side scatter to distinguish lymphocytes in aortic digests. Cells were further gated as shown, for CD11b+/lin- cells. M1 cells were identified as CD11c+/MHC class II hi (left lower panel) while M2 macrophages were identified as CD206+ F4/80 hi (right lower panel).
Figure S5  AngII treatment increases levels of TLR4 in BMDMs from ApoE−/− mice in a dose-dependent manner. BMDMs were starved in DMEM for 8 hours followed by treatment with the indicated concentrations of AngII for 16h. (A) Western blot analysis of TLR4 expression, (B) Densitometry scanning of data in A normalized to GAPDH (*P<0.05, **P<0.01 vs. control).
Supplemental Figure 6

Figure S6 TLR4 knockout attenuates AngII-induced wall thickness in ApoE−/− mice
Figure S7 TLR4 knockout attenuates AngII-induced STAT3 phosphorylation and MMP2 activity. (A) pSTAT3 and tSTAT3 determined by western blot analysis of cell homogenates and MMP2 in the growth medium were determined by zymography. B. Densitometric analysis of data in A normalized to GAPDH (**P< 0.01, compared to control, n=4).